Cynbiose Respiratory works with strategic partners to provide the biopharmaceutical industry with outstanding preclinical non-GLP services.
Cynbiose is a specialty Contract Research Organization (CRO) unique in Europe. The company is specialized in preclinical research services with a core expertise and focus on the non-human primate (NHP) model.
Cynbiose performs exploratory pharmacokinetics and pharmacodynamics studies, early (non-GLP) safety studies, hybrid exploratory designs, and efficacy studies to bridge the gap between preclinical and clinical development.
They also develop innovative clinically relevant models across multiple therapeutic areas to accelerate the discovery of drug candidates, such as infectious diseases, respiratory viral infections (hMPV, hRSV).
The company has also developed unique capabilities for the assessment of nose-to-brain delivery with central pharmacokinetics approaches.
Cynbiose is the parent company of Cynbiose Respiratory.
CEPR (Research Center for Respiratory Diseases)
The CEPR is an academic laboratory (INSERM UMR 1100) located on the joint campus of the Faculty of Medicine and the university hospital in Tours (France).
The aim of the CEPR is to develop translational research to better understand the physiopathology of certain respiratory pathologies and to improve devices for inhaled therapies.